Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing

Jun 12 2017

• By Joseph Haas

Diabetes

Related Content

No Break For Sanofi: Seals Another Diabetes Deal

Nov 06 2015

Lexicon Share Spike On Carcinoid Syndrome Phase III Data

Aug 03 2015

Related Companies

Lexicon Pharmaceuticals, Inc.

Sanofi

Additional Topics

Clinical Trials Research & Development Metabolic Disorders BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.